Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Portfolio Pulse from
Geron Corporation's drug Rytelo, approved in mid-2024, shows promising sales with Q3'24 revenues at $28.2M and Q4'24 projected at $45M-$46M. Despite market exclusivity concerns, GERN has years of sales ahead without generic competition. EU approval for Rytelo is expected in H1'25, offering a near-term catalyst.
February 03, 2025 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron Corporation's Rytelo has shown promising sales figures since its mid-2024 approval, with Q3'24 revenues at $28.2M and Q4'24 projected at $45M-$46M. Despite concerns over market exclusivity, GERN has a significant period before facing generic competition. The potential EU approval in H1'25 for Rytelo in treating lower-risk myelodysplastic syndromes could serve as a near-term catalyst.
The strong sales performance of Rytelo and the potential EU approval are positive indicators for Geron Corporation. The projected increase in Q4'24 revenues suggests growing market acceptance. The expected EU approval in H1'25 could open new markets, providing a significant boost to GERN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100